Immuno-oncology upset in bladder cancer
Nature Reviews Drug Discovery 16, 375 (2017).
doi:10.1038/nrd.2017.108
Author: Asher Mullard
Roche and Genentech's checkpoint inhibitor atezolizumab did not improve overall survival in a confirmatory phase III trial in patients with advanced bladder cancer. The FDA granted accelerated approval to the anti-programmed cell death protein 1 ligand 1 (PDL1) antibody for this indication in 2016 (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 31, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
Search for liquid biopsy grail points the way to drug discovery and development gems
Nature Reviews Drug Discovery 16, 373 (2017).
doi:10.1038/nrd.2017.96
Author: Chris Morrison
An emerging technology for early cancer diagnosis could lead to innovative clinical trial strategies, novel drug combinations and new drug targets. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 31, 2017 Category: Drugs & Pharmacology Authors: Chris Morrison Tags: News and Analysis Source Type: research
Zeroing in on neurodegenerative α -synuclein
Nature Reviews Drug Discovery 16, 371 (2017).
doi:10.1038/nrd.2017.95
Author: Katie Kingwell
In the search for the first disease-modifying therapy for Parkinson disease, drug developers are advancing α-synuclein-targeted agents into proof-of-concept clinical trials. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 31, 2017 Category: Drugs & Pharmacology Authors: Katie Kingwell Tags: News and Analysis Source Type: research
The ovarian cancer drug market
This article discusses the impact of the recent approvals of poly ADP ribose polymerase (PARP) inhibitors on the market for ovarian cancer drugs, as well as potential future treatments such as immunotherapies. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 26, 2017 Category: Drugs & Pharmacology Authors: Jennifer Bamford Rachel M. Webster Tags: News and Analysis Source Type: research
Therapeutic targeting of the angiopoietin – TIE pathway
Nature Reviews Drug Discovery 16, 635 (2017).
doi:10.1038/nrd.2016.278
Authors: Pipsa Saharinen, Lauri Eklund & Kari Alitalo
The endothelial angiopoietin (ANG)–TIE growth factor receptor pathway regulates vascular permeability and pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. Drugs that target the ANG–TIE pathway are in clinical development for oncological and ophthalmological applications. The aim is to complement current vascular endothelial growth (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 19, 2017 Category: Drugs & Pharmacology Authors: Pipsa Saharinen Lauri Eklund Kari Alitalo Tags: Review Source Type: research
Colorectal cancer drugs market
Nature Reviews Drug Discovery 16, 525 (2017).
doi:10.1038/nrd.2017.59
Authors: Sorcha Cassidy & Basharut A. Syed
The market for colorectal cancer therapies, which is currently dominated by drugs targeting vascular endothelial growth factor and epidermal growth factor receptor, is poised for change with the anticipated entry of immunotherapies and other targeted drugs. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 19, 2017 Category: Drugs & Pharmacology Authors: Sorcha Cassidy Basharut A. Syed Tags: News and Analysis Source Type: research
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Nature Reviews Drug Discovery 16, 487 (2017).
doi:10.1038/nrd.2017.22
Authors: Lorenzo Galluzzi, José Manuel Bravo-San Pedro, Beth Levine, Douglas R. Green & Guido Kroemer
Autophagy is central to the maintenance of organismal homeostasis in both physiological and pathological situations. Accordingly, alterations in autophagy have been linked to clinically relevant conditions as diverse as cancer, neurodegeneration and cardiac disorders. Throughout the past decade, autophagy has attracted considerable attention as a (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 19, 2017 Category: Drugs & Pharmacology Authors: Lorenzo Galluzzi Jos é Manuel Bravo-San Pedro Beth Levine Douglas R. Green Guido Kroemer Tags: Review Source Type: research
Neurological disorders: DAMPening damage after stroke
Nature Reviews Drug Discovery 16, 385 (2017).
doi:10.1038/nrd.2017.101
Author: Megan Cully
Much of the tissue injury that occurs following ischaemic stroke is caused by sterile inflammation, which lasts for about a week after the initial artery blockade. Shichita and colleagues have found that increasing transcription of macrophage scavenger receptor 1 (Msr1) reduced neurological deficits (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 19, 2017 Category: Drugs & Pharmacology Authors: Megan Cully Tags: Research Highlight Source Type: research
Neurodegenerative disorders: Ataxin 2 reduction rescues motor defects
Nature Reviews Drug Discovery 16, 384 (2017).
doi:10.1038/nrd.2017.104
Author: Sarah Crunkhorn
Mutations in ATXN2, the gene encoding ataxin 2 — an RNA-binding protein found throughout the body with multiple roles in RNA metabolism — have been implicated in both amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia type 2 (SCA2). Writing in Nature, two new (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 19, 2017 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
Cancer immunotherapy: T cells get a ride
Nature Reviews Drug Discovery 16, 383 (2017).
doi:10.1038/nrd.2017.103
Author: M. Teresa Villanueva
Strategies that inhibit the immune checkpoint blockade (ICB) and reactivate T cells using monoclonal antibodies against programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) have been used to successfully treat immunogenic tumours, and recent efforts have focused on combining this approach with (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 19, 2017 Category: Drugs & Pharmacology Authors: M. Teresa Villanueva Tags: Research Highlight Source Type: research
How much do clinical trials cost?
This article presents the findings of a recent analysis of the costs of clinical trials, providing benchmark data for companies to assess their performance, as well as indicating cost drivers. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 19, 2017 Category: Drugs & Pharmacology Authors: Linda Martin Melissa Hutchens Conrad Hawkins Alaina Radnov Tags: News and Analysis Source Type: research
The antifungal pipeline: a reality check
Nature Reviews Drug Discovery 16, 603 (2017).
doi:10.1038/nrd.2017.46
Author: John R. Perfect
Invasive fungal infections continue to appear in record numbers as the immunocompromised population of the world increases, owing partially to the increased number of individuals who are infected with HIV and partially to the successful treatment of serious underlying diseases. The effectiveness of current antifungal (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 12, 2017 Category: Drugs & Pharmacology Authors: John R. Perfect Tags: Review Source Type: research
Combination products: modernizing the regulatory paradigm
Nature Reviews Drug Discovery 16, 513 (2017).
doi:10.1038/nrd.2017.66
Authors: Nina L. Hunter & Rachel E. Sherman
New opportunities to develop innovative — and often complex — products that combine drugs, devices and/or biological components are rapidly emerging, raising questions about how such products should be regulated. Here, we discuss the ongoing efforts of the FDA to develop a modern, transparent, flexible (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 12, 2017 Category: Drugs & Pharmacology Authors: Nina L. Hunter Rachel E. Sherman Tags: Comment Source Type: research
Market watch: Trends in pharmaceutical company R & D spending: 2005 – 2015
Nature Reviews Drug Discovery 16, 376 (2017).
doi:10.1038/nrd.2017.81
Authors: Richa Dixit & Frank S. David
Pharmaceutical industry trade groups commonly claim that growing revenues (supported by premium prices) are required to drive innovative R&D, whereas critics maintain that drug companies' outsized returns mainly support corporate infrastructures, fuel marketing budgets and enrich investors. In fact, both arguments are incompletely supported by (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 12, 2017 Category: Drugs & Pharmacology Authors: Richa Dixit Frank S. David Tags: News and Analysis Source Type: research
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Nature Reviews Drug Discovery 16, 565 (2017).
doi:10.1038/nrd.2017.33
Authors: Veaceslav Boldescu, Mira A. M. Behnam, Nikos Vasilakis & Christian D. Klein
Infections with flaviviruses, such as dengue, West Nile virus and the recently re-emerging Zika virus, are an increasing and probably lasting global risk. This Review summarizes and comments on the opportunities for broad-spectrum agents that are active against multiple flaviviruses. Broad-spectrum activity is particularly desirable (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - May 5, 2017 Category: Drugs & Pharmacology Authors: Veaceslav Boldescu Mira A. M. Behnam Nikos Vasilakis Christian D. Klein Tags: Review Source Type: research
